Andrew Baum, Pfizer's chief strategy and innovation officer, talked Thursday about the pharmaceutical company's drug ...

The FDA approval of Alnylam’s Amvuttra sets up a three-way race with Pfizer and BridgeBio, which both market transthyretin ...

A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...

An experimental drug appears to reduce the risk of Alzheimer's-related dementia in people destined to develop the disease in their 30s, 40s or 50s, according to the results of a new study. The ...

The first time Dr. Fajgenbaum repurposed a drug, it was in an attempt to save his own life. At 25, while in medical school, ...

For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from ...

Despite advances in anticoagulant therapies, bleeding remains a critical concern.Traditionally, the definition of major ...

The Foundation’s National Volunteer Advocacy Committee provides guidance and support to further strengthen and enhance the ...

Researchers have revealed for the first time how a key protein linked to Parkinson's mutates, leads to cell death in the ...

Canada’s foreign minister said the government would continue to ask for leniency from China for other Canadians in similar ...

Net research and development expenses for the device division increased in 2024 to CAD175,000 from CAD44,000 in 2023, a 400% increase. The increase is attributed to development of a new software ...